Business Wire

BRUSSELS-SIGNAL

Share
Brussels Signal: New Media Outlet Promises to Shake Up EU Coverage

Digital publisher Remedia Europe is preparing a groundbreaking news outlet, Brussels Signal, that promises to provide fresh and candid coverage of EU affairs and the issues that matter most to the citizens of Europe.

Brussels Signal will deliver rigorous reporting and analysis of the European Union. The news outlet aims to shake up the status quo by providing insightful and informed journalism that challenges prevailing ideas and policies, demands genuine accountability from decision-makers, and counters the marginalisation of dissenting voices on the issues facing Europe today.

An early version of Brussels Signal opens May 31 with an invitation to join a live event with the new editors. Other features of the news outlet – including video content and newsletters – will roll out in the coming weeks, with events coming this autumn at the Brussels Signal’s purpose-built studio in the heart of the European Quarter of Brussels.

The new media brand emerges at a time when the EU faces internal differences among Member States that are testing the work of the EU and questioning the shape and substance that European unity will take. External challenges including the war in Ukraine, energy security, migration, and trends in geopolitics are set to try the EU as a global player, and upcoming elections present opportunities for it to demonstrate its ambitions.

Meanwhile, the news industry is seeing consolidation, which means not more voices but fewer. Today’s European citizens demand greater freedom in news media, sources that raise tough questions and encourage unfettered debate; media pluralism is an essential part of this.

“We’re thrilled to introduce Brussels Signal,” said Michael Mosbacher, who played leading roles in the launch of Standpoint and The Critic in the UK and serves as Editor-in-Chief of the new media outlet. “Our team of talented journalists is dedicated to delivering accurate, timely, and insightful coverage of the most important issues affecting people throughout Europe. Our objective is to critically examine the news of the day and present a distinctive alternative viewpoint, offering a captivating source of content that engages and enlightens our audience.”

Justin Stares, a Brussels-based correspondent whose bylines have appeared in The Telegraph, Sunday Telegraph, New York Times, The Guardian, Observer, and other titles, will serve as senior editor for news. Justin is also founder of The Maritime Watch, an EU policy news service, and author of several books, most recently This is Belgium, a political, economic and social analysis of the country that hosts the EU institutions.

The site will feature regular commentary and analysis from well-known and emerging voices, including Douglas Murray, Anne-Elisabeth Moutet, Dominic Green, Kapil Komireddi, Alessandra Bocchi, William Nattrass, Ralph Schoellhammer and Felipe Fernandez-Armesto. Authored newsletters with a regional and thematic focus will highlight developments underreported in Brussels. Plus, engaging video content, including interviews with opinion leaders and podcasts.

“The EU and its Member States remain indispensable in this environment fraught with crisis and conflict, and there’s no question that European institutions and the people of Europe would benefit from a distinctive source of news and insights,” said Patrick Egan, Remedia Europe CEO and publisher of Brussels Signal. “What you see now at Brussels Signal is just the beginning. We’re ramping up our products – newsletters, podcasts and more – in our endeavour to shake up the news media landscape.

“When we look at the current media landscape, we see an opportunity. Rather than sit on the sidelines, I decided to invest my time and money to pursue that opportunity and bring about the change we need. Now we have the seed capital to finally launch with confidence in our news brand and its prospects as a sustainable business, one that will constructively influence the conversation at the European level.”

ENDS

Brussels Signal (https://brusselssignal.eu/) provides rigorous reporting on the important issues affecting citizens across Europe. Challenging the status quo with a focus on delivering insightful coverage of the issues shaping the Europe of today and tomorrow, our seasoned editors and contributors offer a distinct perspective on the news.

For more information about Brussels Signal and to read its coverage, visit www.brusselssignal.eu.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005558/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis

Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release

Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe

Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release

Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news

Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release

Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release

Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye